Bioavailability of subcutaneous 5-fluorouracil: A case report

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 1, 1996, Pages 110-112

  Eatock, M M ^a   Carlin, W ^a   Dunlop, D J ^a   Soukop, M ^a   Watson, D G ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

5 Fluorouracil; Bioavailability; Colorectal cancer; Subcutaneous administration

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; ARTICLE; BLISTER; BOLUS INJECTION; CASE REPORT; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SKIN TOXICITY; STEADY STATE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CARCINOMA; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; SKIN;

EID: 0029869342     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050456     Document Type: Article

References (8)

1. Bates CD, Watson DG, Willmott N, Logan H, Goldberg J (1991) The analysis of 5-fluorouracil in human plasma by gas chromatography-negative ion chemical ionisation mass spectrometry (GC-NICIMS) with stable isotope dilution. J Pharm Biomed Anal 9: 19-21
2. Borner MM, Kneer J, Crevoisier C, Brunner KW, Cerny T (1993) Bioavailability and feasibility of subcutaneous 5-fluorouracil. Br J Cancer 68: 537-539
3. Chabner BA, Myers CE (1989) Clinical pharmacology of cancer chemotherapy: In: DeVita VT, Mellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology. Lippincott, Philadelphia, p 361
4. De-Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, Grange JD, Gonzalez-Canali G, Demuynck B, Louvet C (1988) High dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 24: 1499-1503
5. Heidelberger C, Chandhari NK, Dannenberg P (1957) Fluorinated pyrimidines: a new class of tumour inhibitory compounds. Nature 179: 665-666
6. Leichman CG, Flemming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalil A, Macdonald JS (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13: 1303-1311
7. Presant CA, Wolf W, Waluch V, Wiseman C, Blayney D, Brechner S (1994) Association of intratumoural pharmacokinetics of fluorouracil with clinical response. Lancet 343: 1184-1187
8. Wils JA (1992) High dose fluorouracil: a new perspective in the treatment of colorectal cancer? Semin Oncol 20 [Suppl 3]: 126-130